Numerous studies have been published about the implication of the neurotrophin brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the pathogenesis of several neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis and motor neuron disease. BDNF activates the TrkB receptor with high potency and specificity, promoting neuronal survival, differentiation and synaptic plasticity. Based on the main structural characteristics of LM22A-4, a previously published small molecule that acts as activator of the TrkB receptor, we have designed and synthesized a small data set of compounds. The lead idea for the design of the new compounds was to modify the third position of the LM22A-4, by introducing different substitutions in order to obtain compounds which will have not only better physicochemical properties but selective activity as well. ADME and toxicity profiles of molecules have been evaluated as well as their biological properties through the TrkB receptor and affinity to promote neurite differentiation.
Eur J Med Chem. 2023 Feb 15
Metabolic syndrome is characterized by dysregulated glucose metabolism and is
We are pleased to announce that Innoprot has been recognised
Acetyl-l-carnitine (ALC) is synthesized in the brain, liver, and kidneys
Neural stem cell (NSC) proliferation and differentiation in the mammalian
Allergic conjunctivitis (AC) is the most common form of allergic
The hepatic content of amyloid beta (Aβ) decreases drastically in